Trial Profile
A randomized, double blind trial of LdT (telbivudine) versus lamivudine in adults with compensated chronic hepatitis B
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Feb 2018
Price :
$35
*
At a glance
- Drugs Telbivudine (Primary) ; Lamivudine
- Indications Hepatitis B
- Focus Registrational; Therapeutic Use
- Acronyms GLOBE
- Sponsors Idenix Pharmaceuticals; Merck Sharp & Dohme
- 01 Feb 2018 Results of retrospective analysis assessing effect of HBV subgenotype on treatment response using patient data from NCT00962533, NCT00057265 and NCT00131742 trials published in the Hepatology Research
- 01 Feb 2009 2-year results published in Gastroenterology.
- 20 Dec 2007 Week 52 results published in full in New England Journal of Medicine (NEJM) 357: 2576-2588, No. 25, 20 Dec 2007.